

Special Issue

Recent Developments in Vaccines against Respiratory Pathogens

Message from the Guest Editor

Respiratory tract infections are responsible for millions of deaths annually. Vaccine formulations and policies are constantly updated to provide protection against severe respiratory diseases as RNA viruses continue to evolve. For instance, COVID-19 mRNA vaccines were recommended in the USA in 2022, but these vaccines are being updated to protect against SARS-CoV-2 variants. Specifically, the FDA has approved a monovalent Omicron XBB.1.5 COVID-19 vaccine which targets the current circulating variant. A recently developed COVID-influenza combination vaccine entered Phase 3 clinical trials in 2023. This vaccine was developed to offer dual protection against both influenza and COVID-19 in a single shot, increasing protection during the influenza season. Additionally, in 2023, a maternal RSV vaccine was also approved that is specifically designed to protect women who are 32-36 weeks pregnant during the RSV season. These are all examples of improvements in vaccine safety and effectiveness. We invite scholars developing or evaluating novel vaccine candidates against respiratory pathogens to submit their work to this Special Issue by July 2024.

Guest Editor

Prof. Dr. Renukaradhya J. Gourapura

Center for Food Animal Health, Department of Animal Sciences,
College of Food, Agricultural, and Environmental Sciences, The Ohio
State University, Columbus, OH, USA

Deadline for manuscript submissions

closed (31 July 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/188380

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).